USA - January 20 2023
The U.S. Department of Justice (DOJ) recently announced "the first significant changes" to its Corporate Enforcement Policy (CEP) since…
Wifredo A Ferrer, William F. Gould, Eddie A. Jauregui, Megan Mocho
USA - April 24 2020
Holland & Knight attorneys and policy professionals provide an overview and analysis of the likely wave of congressional oversight and government…
Christopher J Armstrong, Charles E. Borden, Samuel Brown, Christopher "Chris" DeLacy, Leila S. George-Wheeler, Kelsey M. Hayes, Marissa C Serafino, Robert K. "Bob" Tompkins
USA - September 17 2018
Identifying threats and improving network and supply chain security has been an ongoing effort by Congress and the Department of Defense (DoD) for the…
David S. Black, Amy L. Fuentes
USA - January 31 2013
After two years of deliberation, the U.S. Second Circuit Court of Appeals has finally issued its decision in United States v. Caronia, holding that…
Bradley S. Gould
USA - December 6 2012
In United States v. Caronia, No. 09-5006-cr, slip op. (2d Cir. Dec. 3, 2012), the U.S. Court of Appeals for the Second Circuit held that "the government cannot prosecute pharmaceutical manufacturers and their representatives under the [Food, Drug and Cosmetic Act (FDCA)] for speech promoting the lawful, off-label use of [a U.S. Food and Drug Administration] FDA-approved drug."
William F. Gould